GSK has turned to Brooke Shields to get the message out about shingles vaccination. | GSK has turned to Brooke Shields to get ...

GSK plc GSK announced that its therapeutic herpes simplex virus (HSV) vaccine candidate, GSK3943104, did not meet the primary ...

British drugmaker GSK said on Wednesday its experimental herpes simplex virus (HSV) vaccine candidate failed to meet the main ...

British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot ...

Before the FDA approved AstraZeneca’s Fasenra, Nucala was the only therapy for treating eosinophilic granulomatosis with ...

GSK’s GSK phase III study evaluating its blockbuster drug Nucala (mepolizumab), an anti-IL5 biologic, for treating chronic ...

A targeted immunotherapy being developed by iTeos Therapeutics and GSK, it was reported at #ESMO, delivered promising ...

Data from a late-stage study shows that co-administering GSK's RSV and Shingles vaccines together was as effective as giving each separately.

GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix.

Brooke Shields tells PEOPLE on the set of GSK's Thrive@50+ campaign about her optimistic outlook on aging and why she's ...

GSK’s (LSE: GSK) share price is 9% down from its 15 May 12-month traded high of £18.19. This compounds the stock’s already extreme undervaluation against its competitors apparent to me beforehand.

An Illinois mistrial involving the recalled medication Zantac is the latest court decision involving the recalled drug, but ...